文献速递衰弱、肌少症与跌倒老年综合评估老年慢病共病管理

医院衰弱风险评分与住院时长、院内死亡及费用的关联:英格兰全国代表性回顾性队列研究

Association between Hospital Frailty Risk Score and length of hospital stay, hospital mortality, and hospital costs for all adults in England: a nationally representative, retrospective, observational cohort study.
PubMed 文献 · Lancet Healthy Longev · 2025-08-21

结果显示HFRS与三项结局在所有年龄组均显著相关,且关联幅度随年龄增长而增大;作者认为HFRS虽为75岁及以上人群设计,但可扩展用于18岁及以上所有成人。

要点

  • HFRS与住院时长、院内死亡和费用在所有年龄组均显著相关,关联幅度随年龄增长而增大。

核心结论

  • HFRS虽为75岁及以上人群设计,但与18岁及以上所有急诊住院成人的住院时长、院内死亡和住院费用均显著相关,且关联幅度随年龄增长而增大。

研究设计与样本

  • 按HFRS分为零(HFRS=0)、低(0<HFRS<5)、中(5≤HFRS≤15)、高(HFRS>15)四组,分别用泊松模型、概率模型和广义线性模型分析住院时长、院内死亡和费用,并按九个年龄组分别运行。

主要发现

  • 所有年龄组中衰弱风险与住院时长和费用均显著相关,关联幅度随年龄增长而增大。

临床怎么用

  • 可考虑将基于HFRS的衰弱仪表盘从老年人扩展至18岁及以上所有住院成人,以便对年轻人群开展早期生命历程干预以延缓或预防衰弱及相关结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies have shown that the Hospital Frailty Risk Score (HFRS) is significantly associated with length of stay, in-hospital mortality, and costs in people aged 75 years and older. However, its applicability to hospitalised adults of all ages is unclear. We aimed to examine the association between the HFRS and these three outcomes in a nationally representative sample of adults aged 18 years and older, admitted for emergency hospital care. METHODS: The analytical sample comprised 1 478 554 emergency hospital admissions for 653 294 patients-a 5% random sample of all emergency admissions for those aged 18 years and older to any English National Health Service acute hospital between April 1, 2011, and March 31, 2019. Admissions were categorised into zero (HFRS=0), low (0< HFRS <5), intermediate (5≤ HFRS ≤15), or high (HFRS >15) frailty risk categories. We analysed the association between these categories and three outcomes: length of stay (Poisson model), in-hospital death (probit model); and hospital costs (generalised linear model). Models controlled for patient characteristics and temporal effects and were run separately across nine age groups (18-24 years, 25-34 years, 35-44 years, 45-54 years, 55-64 years, 65-74 years, 75-84 years, 85-94 years, and ≥95 years). FINDINGS: The prevalence of high frailty risk increased with age, from 210 (0·2%) of 96 296 admissions for those aged 18-24 years to 9414 (42·0%) of 22 431 admissions for those aged 95 years and older. There were significant associations between frailty risk and both length of stay and costs across all age groups; the magnitude of the associations increased with age. For example, for those aged 18-24 years with high frailty risk, length of stay was 4·5 days (95% CI 3·8-5·3) longer and costs were £1217 higher (796-1638) than for someone with a zero frailty risk. For those aged 95 years and older with high frailty risk, length of stay was 15·3 days (13·5-17·1) longer and costs were £2557 higher (2234-2880) than for someone with a zero frailty risk. The association between frailty risk and in-hospital mortality increased up to age 65-74 years-those in this age group with high frailty risk had a probability of dying in hospital that was 2·3% greater (1·99-2·61) than those with zero frailty risk. This association decreased for older age groups. INTERPRETATION: Although designed for people aged 75 years and older, the HFRS was significantly associated with length of stay, in-hospital death, and hospital costs for all adults admitted to hospital, with a greater magnitude of effect with increasing age. Frailty dashboards that use the HFRS for older people could be extended to all people aged 18 years and older, offering the potential for holistic, frailty attuned interventions for younger people, such as earlier life course interventions to delay or prevent frailty and related outcomes. FUNDING: National Institute for Health and Care Research.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Street A, Maynou L, Blodgett JM, et al. Association between Hospital Frailty Risk Score and length of hospital stay, hospital mortality, and hospital costs for all adults in England: a nationally representative, retrospective, observational cohort study. Lancet Healthy Longev. 2025. PMID: 40850326. doi:10.1016/j.lanhl.2025.100740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。